**Table S4. Analysis of migratory DFC phenotypes in integrin morphants at 80-90% epiboly**

| Marker | Injection stage | Morpholino | mRNA | $n_T$ | $n_{exp}$ | WT | Mutant | Absent |
|---|---|---|---|---|---|---|---|---|
| *cas* | 1 to 4 cell | Uninjected | – | 124 | 5 | 77.9±6.9% | 19.9±6.8% | 2.2±2.5% |
| | | 1.75 ng $\alpha V1miss$ | – | 51 | 2 | 75.7±6.1% | 17.1±4.0% | 7.1±10.1% |
| | | None | 200 pg $m\alpha V$ | 19 | 2 | 63.3±4.7% | 26.7±9.4% | 16.1±8.6% |
| | | 1.25 ng $\alpha V1$ | – | 69 | 4 | 17.6±6.3% | 69.3±9.5% | 13.2±7.3% |
| | | 1.25 ng $\alpha V1$ | 200 pg $m\alpha V$ | 23 | 2 | 56.3±1.1% | 43.7±1.1% | 0% |
| | | 1.75 ng $\alpha V2$ | – | 59 | 4 | 23.9±6.8% | 67.9±9.3% | 8.2±3.4% |
| | | 1.75 ng $\alpha V2$ | 200 pg $m\alpha V$ | 19 | 2 | 52.2±11.0% | 42.8±18.1% | 5.0±7.1% |
| | | 5.00 ng $\alpha VEI10$ | – | 23 | 2 | 47.3±15.5% | 52.7±15.5% | 0% |
| | | 0.75 ng $\beta 1b1$ | – | 40 | 3 | 21.1±18.3% | 72.2±18.0% | 6.7±8.2% |
| | | 5.00 ng $\beta 1bEI10$ | – | 23 | 2 | 48.5±21.4% | 51.5±21.4% | 0% |
| *sox17* | 1 to 4 cell | Uninjected | – | 53 | 3 | 68.8±7.5% | 22.9±7.9% | 8.3±4.8% |
| | | 1.75 ng $\alpha V1miss$ | – | 17 | 2 | 70.8±4.2% | 12.5±12.5% | 16.7±16.7% |
| | | 1.25 ng $\alpha V1$ | – | 27 | 2 | 19.2±4.2% | 53.3±13.3% | 27.5±19.2% |
| | | 1.75 ng $\alpha V2$ | – | 28 | 2 | 32.5±7.5% | 47.5±27.5% | 20.0±20.0% |
| | | 5.00 ng $\alpha VEI10$ | – | 12 | 1 | 58.3% | 33.3% | 8.3% |
| | | 0.75 ng $\beta 1b1$ | – | 18 | 2 | 37.0±8.4% | 33.1±24.0% | 29.9±15.6% |
| | | 5.00 ng $\beta 1bEI10$ | – | 21 | 1 | 38.1% | 47.6% | 14.3% |
| *ntl* | 1 to 4 cell | Uninjected | – | 42 | 3 | 79.0±1.4% | 16.5±3.9% | 4.5±4.5% |
| | | 1.75 ng $\alpha V1miss$ | – | 25 | 3 | 68.1±3.7% | 8.3±8.3% | 23.6±6.1% |
| | | 1.25 ng $\alpha V1$ | – | 53 | 4 | 29.2±7.6% | 60.9±2.0% | 9.9±5.8% |
| | | 5.00 ng $\alpha VEI10$ | – | 46 | 2 | 36.9±0.1% | 40.4±7.0% | 22.7±6.9% |
| | | 0.75 ng $\beta 1b1$ | – | 31 | 3 | 34.2±4.6% | 58.6±3.8% | 8.3±8.3% |
| | | 5.00 ng $\beta 1bEI10$ | – | 29 | 2 | 41.4±0.2% | 58.6±0.2% | 0% |
| *cas* | 512-1000 cell | Uninjected | – | 63 | 2 | 80.6±10.3% | 11.1±1.5% | 8.3±11.8% |
| | | 2. 50 ng $\alpha V1miss$ | – | 47 | 3 | 75.5±3.6% | 19.2±7.1% | 5.3 ±3.6% |
| | | 1.25 ng $\alpha V1$ | – | 48 | 3 | 36.8±5.3% | 41.5±8.8% | 21.7±3.8% |
| | | 1.75 ng $\alpha V2$ | – | 12 | 1 | 41.7% | 41.7% | 16.7% |
| | | 0.75 ng $\beta 1b1$ | – | 39 | 3 | 36.1±9.0% | 42.6±6.0% | 21.3±14.7% |
| | | 5.00 ng $\beta 1bEI10$ | – | 25 | 2 | 23.4±7.3% | 64.0±0.5% | 12.7±7.8% |